- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02496650
Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU
Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal Syndrome in the ICU: a Randomised Controlled Study
Study Overview
Detailed Description
Ethical issues This study was approved by the Bogomolets National Medical University ethics committee and a written informed concern was obtained from the patient, the patient's family or a legal representative.
Study design This randomized, single-center, controlled study was conducted in the adult ICU at private hospital "Boris" in Kiyv (Ukraine). The inclusion criteria were: age 18 or older, signed informed concern, within 2 hours of ICU admission, diagnosed alcohol withdrawal syndrome or alcohol withdrawal delirium by DSM IV criteria (). The exclusion criteria were age younger than 18 or older than 75, history of use or withdrawal states of other psychoactive substances, general anesthesia during last 24 hours or known other sedatives use, severe neurologic disorder (traumatic brain injury, acute stroke, severe dementia), pregnancy or lactation, severe comorbidities (severe heart failure, acute myocardial infarction, heart rate <50/min, glomerular filtration rate < 30 ml/min, liver failure Child-Pugh class C), known allergy to the study medication.
After primary patient assessment the target sedation level was set individually and study treatment begun. Eligible participants were randomly assigned in a 1:1 ratio to the intervention (group D) and control groups using random assignment in block of four. In group D DEX infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. In group K BZD boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication in both groups for severe agitation or hallucinations.
Study outcomes and statistical analysis The primary efficacy outcomes were 24-hour diazepam consumption after study begins and cumulative diazepam dose required over the course of ICU stay.
The secondary efficacy outcomes include:
- length of ICU stay and intubation rates;
- sedation quality: the time of target sedation (proportion of time in target sedation range (in most cases RASS score 0 to -2) to the total sedation time); the time of insufficient sedation (duration of ineffective sedation (in most cases RASS score ≥+2) to the total sedation time); the time of oversedation (duration of excessive sedation (in most cases RASS ≤-3) to the total sedation time); the number of rescue sedation boluses and sedation stops in 24 hours;
- communication quality (from 0 to 10, were 0 - uncommunicative, 10 - patient communicates well) and ability to asses pain with Visual Analogue Scale (VAS);
- haloperidol requirements and cumulative dose during ICU stay. Safety was estimate by monitoring vital sighs, ECG, laboratory tests (paO2, SaO2, blood sugar), and adverse events. Adverse events were evaluated if systolic blood pressure was lower than 90 mm Hg of higher than 160 mm Hg or heart rate was lower than 50/min or higher than 110/min; desaturation were estimated as SpO2 (or SaO2) lower than 90%; hypoglycemia was defined as serum glucose lower than 4 mmol/L and hyperglycemia as higher than 10 mmol/L. Intervention for bradycardia, tachycardia, hypertension and hypotension were titration or interruption of study agent or drug therapy.
Sedation was assessed using Richmond Agitation Sedation Scale (RASS) and AWS symptoms severity - with Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar). RASS was monitored every 2-6 hours and prior to rescue therapy, CIWA-Ar was assessed on the daily basis during sedation stops.
Randomization sequence was generated using a computer algorithm [www.random.org]. Both randomization and data analysis were conducted by independent blind member of research team.
A statistical analysis was performed using Statistics 6.0 and R software. Categorical data are presented as proportions; continuous data - as medians (InterQuartile Range, IQR 25-75%). Chi-square testing demonstrates that all variables under study are discrete. To assess significances two-tailed Mann-Whitney U test and Fisher exact test were used. A P-value of less than 0.05 defined as significant.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 18 or older,
- signed informed concern,
- within 2 hours of ICU admission,
- diagnosed alcohol withdrawal syndrome or alcohol withdrawal delirium by DSM IV criteria
Exclusion Criteria:
- younger than 18 or older than 75,
- history of use or withdrawal states of other psychoactive substances,
- general anesthesia during last 24 hours or known other sedatives use,
- severe neurologic disorder (traumatic brain injury, acute stroke, severe dementia),
- pregnancy or lactation,
- severe comorbidities (severe heart failure, acute myocardial infarction, heart rate <50/min, glomerular filtration rate < 30 ml/min, liver failure Child-Pugh class C),
- known allergy to the study medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group D
Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough.
Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
|
DEX infusion in doses 0,2-1,4 μg/kg/hr
Other Names:
|
No Intervention: Group C
Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration).
Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
24-hour diazepam consumption
Time Frame: 24 hours
|
24-hour diazepam consumption was estimated after the study begins.
|
24 hours
|
Cumulative diazepam dose
Time Frame: 30 days
|
Diazepam dose required over the course of ICU stay
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Length of ICU stay
Time Frame: 30 days
|
30 days
|
|
the time of target sedation
Time Frame: 24 hours
|
proportion of time in target sedation range (in most cases RASS score 0 to -2) to the total sedation time
|
24 hours
|
the number of rescue sedation boluses
Time Frame: 24 hours
|
24 hours
|
|
the number of sedation stops
Time Frame: 24 hours
|
24 hours
|
|
Adverse events
Time Frame: 30 days
|
hypotension, hypertension, tachycardia, bradicardia, desaturation
|
30 days
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 234
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Withdrawal State
-
VA Salt Lake City Health Care SystemCompleted
-
Denver Health and Hospital AuthorityTerminatedAlcohol Withdrawal Delirium | Alcohol Withdrawal Associated Autonomic Hyperactivity | Alcohol Withdrawal Hallucinosis | Alcohol Withdrawal-Induced Delirium TremensUnited States
-
University of Colorado, DenverWithdrawnAlcohol WithdrawalUnited States
-
Stanford UniversityCompletedAlcohol WithdrawalUnited States
-
Unity Health TorontoTerminatedAlcohol Withdrawal | Alcohol Withdrawal Delirium | Alcohol Withdrawal SeizuresCanada
-
Medical University of ViennaCompletedPsychophysiologic Reaction | Alcohol WithdrawalAustria
-
Instituto Nacional de Psiquiatría Dr. Ramón de...CompletedDrug-withdrawal. | Drug Abuse | Drug-induced Depressive State | AOD Craving | AODR Depressive StateMexico
-
University Hospital, MontpellierCompletedAddiction | Alcohol Use Disorder | Alcohol Withdrawal SyndromeFrance
-
Jubilee Mission Medical College and Research InstituteINCRE fellowship from DBT, govt of IndiaCompletedAlcohol Withdrawal Symptoms | Delirium Tremens (DTs)
-
Jonathan RosensonAlameda County Medical CenterCompleted
Clinical Trials on Dexmedetomidine
-
Cairo UniversityUnknownSpinal Anesthesia DurationEgypt
-
Guangzhou Women and Children's Medical CenterCompletedAmbulatory Surgical ProceduresChina
-
The First Affiliated Hospital with Nanjing Medical...CompletedPostoperative Pain | Breast Feeding | Analgesia ObstetricalChina
-
Seoul National University Bundang HospitalCompleted
-
Guangzhou General Hospital of Guangzhou Military...CompletedPharmacodynamic InteractionChina
-
University Hospital DubravaRecruitingAortic Valve Stenosis | Systemic Inflammatory ResponseCroatia
-
Guangzhou General Hospital of Guangzhou Military...Completed
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownArteriovenous MalformationChina
-
Guangzhou General Hospital of Guangzhou Military...UnknownCombined Spinal-epidural AnesthesiaChina
-
Eye & ENT Hospital of Fudan UniversityCompletedAgitated; State, Acute Reaction to StressChina